Serotonin Signaling in Pulmonary Hypertension

Abstract

HomeCirculation ResearchVol. 98, No. 10Serotonin Signaling in Pulmonary Hypertension Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBSerotonin Signaling in Pulmonary Hypertension Mark de Caestecker Mark de CaesteckerMark de Caestecker From the Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tenn. Search for more papers by this author Originally published26 May 2006https://doi.org/10.1161/01.RES.0000225927.04710.33Circulation Research. 2006;98:1229–1231Serotonin (5-HT, 5-hydroxytryptamine) has long been recognized as one of the most potent naturally occurring pulmonary vasoconstrictors.1 It was first implicated in the pathogenesis of pulmonary arterial hypertension (PAH) after an outbreak of the disease in Switzerland in the 1960’s among patients taking aminorex fumarate, an appetite suppressant that inhibits serotonin uptake by platelets.2 Since that time further outbreaks of PAH have been identified in Europe and the USA associated with the use of fenfluramine-derivate anorexigens,3–5 eventually leading to their withdrawal from the world market in 1997. Although this was, at least in retrospect, a predictable tragedy, it has ironically opened avenues of research into the biology of serotonin signaling in PAH. As fenfluramine-derivatives are substrates for the serotonin transporter (5-HTT, SERT) proteins,6 this suggests that abnormal SERT expression or functional activity could play a role in the pathogenesis of PAH. There is now a body of evidence supporting this hypothesis that provides hope for the development of effective therapeutic strategies targeting specific components of this signaling pathway in patients with these diseases.Most of the serotonin produced in the body is secreted by enterochromaffin cells of the intestine into the portal circulation where it is partially metabolized by the liver. However, levels of free circulating serotonin are maintained in the low nanomolar range through energy-dependent SERT-mediated transport into platelets. This led some researchers to hypothesize that fenfluramines might cause PAH by increasing free plasma levels of serotonin. However, this hypothesis is inconsistent with the observation that chronic treatment with fenfluramine-derivatives if anything reduces plasma levels of serotonin.6 This suggests that other SERT-related effects promote PAH in susceptible patients. This is supported by the observation that patients with idiopathic PAH have increased frequency of the so called L-type polymorphism in the SERT promotor, which is associated with increased SERT expression and activity in platelets and pulmonary artery smooth muscle cells (PASMCs).7 These studies have recently come under fire as more extensive analyses have failed to confirm an association between the L-genotype and idiopathic or familial PAH.8,9 Nonetheless, subgroup analysis suggests that the homozygous LL-SERT genotype is associated with early onset of disease in patients with familial PAH.9 Furthermore, analysis of cultured PASMCs indicates that SERT expression is regulated independently of the L-genotype but correlates with severity of pulmonary hypertension (PH) in patients with secondary PH associated with other cardiopulmonary diseases.10 These findings support the concept that increased SERT expression may be a mechanism or indicator of disease progression in patients with different forms of PH.Experimental data support the hypothesis that alterations in SERT expression could play a role in the pathogenesis of PH. SERT is expressed in pulmonary vascular endothelial and smooth muscle cells. Furthermore, serotonin induces proliferation of cultured PASMCs and adventitial fibroblasts, and this effect is inhibited by incubation with serotonin re-uptake inhibitors (SSRIs).11–13 These agents bind with high affinity to SERT proteins and block serotonin uptake,6 suggesting that the mitogenic effects of serotonin are dependent on SERT. There is also evidence that SERT plays a role in the pathogenesis of experimental PH. Treatment with SSRIs abrogates PH in chronically hypoxic mice and rats with monocrotaline-induced PH.14,15 Furthermore, mice carrying null mutations at the SERT locus are protected from the development of PH associated with prolonged hypoxia.16 The latter findings are complicated, as the same study shows that acute hypoxic pulmonary vasoconstriction is enhanced in SERT mutant mice. These findings are supported by the observation that SSRIs potentiate serotonin-dependent pulmonary vascular contractility in Fawn Hooded rats,17 and suggest that SERT has opposing effects in acute versus chronic phases of hypoxic PH. To evaluate the effects of SERT overexpression, YAC transgenic mice carrying extra copies of the SERT gene (along with all of its normal cis-acting regulatory elements) have been used to overexpress SERT in its endogenous distribution domains.18 These mice develop spontaneous PH and more severe pulmonary vascular remodeling in response to chronic hypoxia. These findings support the hypothesis that SERT overexpression plays a role in exacerbating pulmonary vascular disease in patients with PAH, but do not discriminate between pulmonary versus systemic effects of SERT overexpression. This is of importance as there is evidence that PH in Fawn Hooded rats is caused by an inherited defect in platelet serotonin storage.19 In addition there is a case report of a patient with familial platelet storage disease developing PAH associated with increased circulating levels of serotonin.20 These observations suggest that defective serotonin transport by platelets could play a role in regulating pulmonary vascular responses and, conversely, raise the question as to whether overexpression of SERT in the pulmonary vasculature plays any role in the pathogenesis of PAH.The article by Guignabert and colleagues in this issue of Circulation Research provides the first direct evidence that SERT overexpression in the vasculature can promote pulmonary vascular remodeling.21 In these studies, the authors use a 2.2-kb fragment of the mouse SM-22 promotor to selectively drive transgenic expression of SERT in pulmonary (and systemic) arterial smooth muscle cells. These mice develop spontaneous PH along with progressively severe pulmonary vascular remodeling and proliferation. They also show increased susceptibility to PH induced by chronic hypoxia and treatment with an active (in mice) monocrotaline-derivative. These findings are consistent with observations in SERT null and SERT YAC transgenic mice,16,18 and suggest that overexpression of SERT in the vascular smooth muscle cells may account for SERT-dependent effects in the pulmonary vasculature described in these earlier studies. The precise mechanism by which SERT mediates these effects remains unclear. However, the authors do show that SM-22 5-HTT transgenic mice have decreased expression of two voltage-gated potassium channels, Kv1.5 and Kv2.1, in the lung. These findings are supported by recent data demonstrating SSRI (fluoxetine) sensitive downregulation of Kv channel activity by serotonin in rat PASMCs.22 As downregulation of Kv channels protects against apoptosis in pulmonary vascular smooth muscle cells,23 these findings could account for the increased pulmonary vascular remodeling seen in these mice.These studies leave unanswered questions regarding the signaling pathways responsible for PH associated with SERT overexpression. Underlying these issues is an ongoing debate on the relative contributions of SERT versus serotonin receptor signaling in mediating pulmonary vascular effects of serotonin. Studies from the Eddahibi and Adnot laboratory suggest that SERT signaling is both necessary and sufficient to mediate serotonin-induced proliferation of pulmonary vascular smooth muscle cells.7,10,12 Furthermore, in vivo studies from the same group indicate that SERT signaling accounts for most, if not all, of the serotonin-dependent remodeling and vascular smooth muscle proliferation seen in hypoxic and monocrotaline-induced models of PH.14,15 In contrast, other groups have shown that the same in vitro and in vivo responses can be modified through pharmacological or genetic inhibition of different serotonin receptors, including 5-HT1B/D, 5-HT2A, or 5-HT2B.11,13,24,25 These discrepancies may be attributable to species differences, cell culture conditions, or differences in selectivity and efficiency of these inhibitors, especially when used for in vivo studies. However, a common theme from a number of in vitro studies is that SERT inhibition and serotonin receptor antagonism have the capacity to block the same mitogenic responses in pulmonary vascular cells.11,13 These effects may result from cross-talk between signaling pathways that are activated independently by SERT and serotonin receptors following treatment with serotonin. A good example of this comes from a series of in vitro studies in which the signaling pathways regulating serotonin-induced growth of bovine PASMCs were evaluated (Figure).26–28 These studies show that SERT signaling generates reactive oxygen species (ROS), which induce phosphorylation of p42/44 ERK MAP Kinases.26 However, serotonin-induced proliferation also requires activation Rho Kinase by the 5-HT1B/D receptors.28 This enables nuclear translocation of ERK and activation of GATA4-dependent transcriptional pathways involved in promoting cell proliferation.27,28 As Rho kinase activation also promotes hypoxic pulmonary vasoconstriction,29 these findings suggest a mechanism that could explain the observation that loss of SERT expression in SERT null mutant mice enhances acute hypoxic pulmonary vasoconstriction.16 In the absence of the serotonin transporter, increased levels of serotonin at the cell surface could enhance 5-HT1B/D signaling and promote Rho kinase-dependent vasoconstriction. Download figureDownload PowerPointSchematic representation of signaling pathways and cross-talk between SERT and the serotonin receptor 5-HT1B/D involved in regulating serotonin induced proliferation of bovine PASMCsWhile these observations provide a model to illustrate the nature and functional impact of cross talk between these signaling pathways, the complexity of these interactions is only beginning to be explored. Detailed mapping and functional evaluation of serotonin receptors in the pulmonary vasculature has yet to be performed (more than 15 serotonin receptors have been identified). In addition, the impact of other non-serotonin signaling pathways has to be taken into account as these are likely to have an impact on the balance of serotonin-dependent responses in the intact vasculature. For example, recent studies have demonstrated functional interaction between serotonin and BMP signaling in PH.30 Mice carrying heterozygous null mutations of the BMP type II receptor exhibit increased pulmonary vascular contractility in responses to serotonin. This is associated with enhanced serotonin-induced proliferation and phosphorylation of p42/44 ERK MAPK in isolated PASMCs, indicating that defective BMP signaling enhances serotonin-dependent responses in these cells. To complicate matters further, there is evidence that the nature of serotonin receptor and transporter signaling may differ significantly in cells derived from different species. This is exemplified by the recent observation that phosphorylation of ERK MAPK in human PASMCs is dependent on 5-HT1B/D, whereas nuclear translocation of phosphorylated ERK is dependent on the generation of ROS by SERT.31 This contrasts with studies outlined above using bovine PASMCs (Figure). These findings serve to illustrate the fact that we still have a long way to go before we can pretend to understand the complexity of serotonin signaling in the context of human disease. However, the body of published work on serotonin signaling along with the elegant in vivo studies reported in this issue of the Journal establishes the basic paradigms of serotonin signaling that are likely to be involved in the pathogenesis of pulmonary vascular disease in patients with PH.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.The author thanks Regina Day from The Uniformed Services University of the Health Sciences for comments and assistance in formulating this manuscript.FootnotesCorrespondence to Mark de Caestecker, Assistant Professor, Division of Nephrology, Vanderbilt University Medical Center, S-3223, Medical Center North, 1161 21st St South, Nashville, TN 37232-2372. E-mail [email protected] References 1 Rudolph AM, Paul MH. Pulmonary and systemic vascular response to continuous infusion of 5-hydroxytryptamine (serotonin) in the dog. Am J Physiol. 1957; 189: 263–268.CrossrefMedlineGoogle Scholar2 Gurtner HP. Aminorex and pulmonary hypertension. A review. Cor Vasa. 1985; 27: 160–171.MedlineGoogle Scholar3 Simonneau G, Fartoukh M, Sitbon O, Humbert M, Jagot JL, Herve P. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest. 1998; 114 (3 Suppl): 195S–199S.CrossrefMedlineGoogle Scholar4 Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996; 335: 609–616.CrossrefMedlineGoogle Scholar5 Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North Am pulmonary hypertension. Chest. 2000; 117: 870–874.CrossrefMedlineGoogle Scholar6 Rothman RB, Baumann MH. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther. 2002; 95: 73–88.CrossrefMedlineGoogle Scholar7 Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, Adnot S. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest. 2001; 108: 1141–1150.CrossrefMedlineGoogle Scholar8 Machado RD, Koehler R, Glissmeyer E, Veal C, Suntharalingam J, Kim M, Carlquist J, Town M, Elliott CG, Hoeper M, Fijalkowska A, Kurzyna M, Thomson JR, Gibbs SR, Wilkins MR, Seeger W, Morrell NW, Gruenig E, Trembath RC, Janssen B. Genetic association of the serotonin transporter in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006; 173: 793–797.CrossrefMedlineGoogle Scholar9 Willers ED, Newman JH, Loyd JE, Robbins IM, Wheeler LA, Prince MA, Stanton KC, Cogan JA, Runo JR, Byrne D, Humbert M, Simonneau G, Sztrymf B, Morse JA, Knowles JA, Roberts KE, McElroy JJ, Barst RJ, Phillips JA 3rd. Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006; 173: 798–802.CrossrefMedlineGoogle Scholar10 Marcos E, Fadel E, Sanchez O, Humbert M, Dartevelle P, Simonneau G, Hamon M, Adnot S, Eddahibi S. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res. 2004; 94: 1263–1270.LinkGoogle Scholar11 Pitt BR, Weng W, Steve AR, Blakely RD, Reynolds I, Davies P. Serotonin increases DNA synthesis in rat proximal and distal pulmonary vascular smooth muscle cells in culture. Am J Physiol. 1994; 266 (2 Pt 1): L178–L186.MedlineGoogle Scholar12 Eddahibi S, Fabre V, Boni C, Martres MP, Raffestin B, Hamon M, Adnot S. Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin. Circ Res. 1999; 84: 329–336.CrossrefMedlineGoogle Scholar13 Welsh DJ, Harnett M, MacLean M, Peacock AJ. Proliferation and signaling in fibroblasts: role of 5-hydroxytryptamine2A receptor and transporter. Am J Respir Crit Care Med. 2004; 170: 252–259.CrossrefMedlineGoogle Scholar14 Marcos E, Adnot S, Pham MH, Nosjean A, Raffestin B, Hamon M, Eddahibi S. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med. 2003; 168: 487–493.CrossrefMedlineGoogle Scholar15 Guignabert C, Raffestin B, Benferhat R, Raoul W, Zadigue P, Rideau D, Hamon M, Adnot S, Eddahibi S. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation. 2005; 111: 2812–2819.LinkGoogle Scholar16 Eddahibi S, Hanoun N, Lanfumey L, Lesch KP, Raffestin B, Hamon M, Adnot S. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest. 2000; 105: 1555–1562.CrossrefMedlineGoogle Scholar17 Morecroft I, Loughlin L, Nilsen M, Colston J, Dempsie Y, Sheward J, Harmar A, MacLean MR. Functional interactions between 5-hydroxytryptamine receptors and the serotonin transporter in pulmonary arteries. J Pharmacol Exp Ther. 2005; 313: 539–548.CrossrefMedlineGoogle Scholar18 MacLean MR, Deuchar GA, Hicks MN, Morecroft I, Shen S, Sheward J, Colston J, Loughlin L, Nilsen M, Dempsie Y, Harmar A. Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation. 2004; 109: 2150–2155.LinkGoogle Scholar19 Gonzalez AM, Smith A, Emery C, Higenbottam T. Pulmonary hypertension, family and environment. J Hum Hypertens. 1997; 11: 559–561.CrossrefMedlineGoogle Scholar20 Herve P, Drouet L, Dosquet C, Launay JM, Rain B, Simonneau G, Caen J, Duroux P. Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin. Am J Med. 1990; 89: 117–120.CrossrefMedlineGoogle Scholar21 Guignabert C, Izikki M, Tu LI, Li Z, Zadigue P, Barlier-Mur AM, Hanoun N, Rodman D, Hamon M, Adnot S, Eddahibi S. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res. 2006; 98: 1323–1330.LinkGoogle Scholar22 Cogolludo A, Moreno L, Lodi F, Frazziano G, Cobeno L, Tamargo J, Perez-Vizcaino F. Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells: role of 5-HT2A receptors, caveolin-1, and KV1.5 channel internalization. Circ Res. 2006; 98: 931–938.LinkGoogle Scholar23 Mandegar M, Yuan JX. Role of K+ channels in pulmonary hypertension. Vascul Pharmacol. 2002; 38: 25–33.CrossrefMedlineGoogle Scholar24 Keegan A, Morecroft I, Smillie D, Hicks MN, MacLean MR. Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935. Circ Res. 2001; 89: 1231–1239.CrossrefMedlineGoogle Scholar25 Launay JM, Herve P, Peoc’h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med. 2002; 8: 1129–1135.CrossrefMedlineGoogle Scholar26 Lee SL, Wang WW, Finlay GA, Fanburg BL. Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion. Am J Physiol. 1999; 277 (2 Pt 1): L282–L291.CrossrefMedlineGoogle Scholar27 Suzuki YJ, Day RM, Tan CC, Sandven TH, Liang Q, Molkentin JD, Fanburg BL. Activation of GATA-4 by serotonin in pulmonary artery smooth muscle cells. J Biol Chem. 2003; 278: 17525–17531.CrossrefMedlineGoogle Scholar28 Liu Y, Suzuki YJ, Day RM, Fanburg BL. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res. 2004; 95: 579–586.LinkGoogle Scholar29 Moudgil R, Michelakis ED, Archer SL. Hypoxic pulmonary vasoconstriction. J Appl Physiol. 2005; 98: 390–403.CrossrefMedlineGoogle Scholar30 Long L, MacLean MR, Jeffery TK, Morecroft I, Yang X, Rudarakanchana N, Southwood M, James V, Trembath RC, Morrell NW. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res. 2006; 98: 818–827.LinkGoogle Scholar31 Lawrie A, Spiekerkoetter E, Martinez EC, Ambartsumian N, Sheward WJ, MacLean MR, Harmar AJ, Schmidt AM, Lukanidin E, Rabinovitch M. Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ Res. 2005; 97: 227–235.LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Snider J and Merryman W (2021) 5-HT2B Receptor in Cardiopulmonary Disease 5-HT2B Receptors, 10.1007/978-3-030-55920-5_10, (165-187), . Sakarin S, Surachetpong S and Rungsipipat A (2020) The Expression of Proteins Related to Serotonin Pathway in Pulmonary Arteries of Dogs Affected With Pulmonary Hypertension Secondary to Degenerative Mitral Valve Disease, Frontiers in Veterinary Science, 10.3389/fvets.2020.612130, 7 Yuan C, Chen H, Hou H, Wang J, Yang Q and He G (2020) Protein biomarkers and risk scores in pulmonary arterial hypertension associated with ventricular septal defect: integration of multi-omics and validation, American Journal of Physiology-Lung Cellular and Molecular Physiology, 10.1152/ajplung.00167.2020, 319:5, (L810-L822), Online publication date: 1-Nov-2020. Kalani C, Garcia I, Ocegueda-Pacheco C, Varon J and Surani S The Innovations in Pulmonary Hypertension Pathophysiology and Treatment: What are our Options!, Current Respiratory Medicine Reviews, 10.2174/1573398X15666190117133311, 14:4, (189-203) Aiello R, Bourassa P, Zhang Q, Dubins J, Goldberg D, De Lombaert S, Humbert M, Guignabert C, Cavasin M, McKinsey T and Paralkar V (2016) Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension, Journal of Pharmacology and Experimental Therapeutics, 10.1124/jpet.116.237933, 360:2, (267-279), Online publication date: 1-Feb-2017. Rich S (2012) Pulmonary Hypertension Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 10.1016/B978-1-4377-0398-6.00078-0, (1696-1718), . Wei L, Liu Y, Kaneto H and Fanburg B (2010) JNK regulates serotonin-mediated proliferation and migration of pulmonary artery smooth muscle cells, American Journal of Physiology-Lung Cellular and Molecular Physiology, 10.1152/ajplung.00281.2009, 298:6, (L863-L869), Online publication date: 1-Jun-2010. Guignabert C, Tu L, Izikki M, Dewachter L, Zadigue P, Humbert M, Adnot S, Fadel E and Eddahibi S (2009) Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22α‐targeted overexpression of the serotonin transporter, The FASEB Journal, 10.1096/fj.09-131664, 23:12, (4135-4147), Online publication date: 1-Dec-2009. Shah S, Gomberg-Maitland M, Thenappan T and Rich S (2009) Selective Serotonin Reuptake Inhibitors and the Incidence and Outcome of Pulmonary Hypertension, Chest, 10.1378/chest.08-2823, 136:3, (694-700), Online publication date: 1-Sep-2009. Belik J (2008) Fetal and Neonatal Effects of Maternal Drug Treatment for Depression, Seminars in Perinatology, 10.1053/j.semperi.2008.08.001, 32:5, (350-354), Online publication date: 1-Oct-2008. Shet A, Hoffmann T, Jirouskova M, Janczak C, Stevens J, Adamson A, Mohandas N, Manci E, Cynober T and Coller B (2008) Morphological and functional platelet abnormalities in Berkeley sickle cell mice, Blood Cells, Molecules, and Diseases, 10.1016/j.bcmd.2008.01.008, 41:1, (109-118), Online publication date: 1-Jul-2008. van der Horst I, Reiss I and Tibboel D (2014) Therapeutic targets in neonatal pulmonary hypertension: linking pathophysiology to clinical medicine, Expert Review of Respiratory Medicine, 10.1586/17476348.2.1.85, 2:1, (85-96), Online publication date: 1-Feb-2008. Laudi S, Trump S, Schmitz V, West J, McMurtry I, Mutlak H, Christians U, Weimann J, Kaisers U and Steudel W (2007) Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin, American Journal of Physiology-Lung Cellular and Molecular Physiology, 10.1152/ajplung.00110.2006, 293:3, (L630-L638), Online publication date: 1-Sep-2007. Bonniaud P (2007) Les souris transgéniques surexprimant le transporteur de la sérotonine dans leurs cellules musculaires lisses développent une hypertension artérielle pulmonaire, Revue des Maladies Respiratoires, 10.1016/S0761-8425(07)91633-2, 24, (16-18), Online publication date: 1-Jun-2007. Faber J, Szymeczek C, Cotecchia S, Thomas S, Tanoue A, Tsujimoto G and Zhang H (2007) α 1 -Adrenoceptor-dependent vascular hypertrophy and remodeling in murine hypoxic pulmonary hypertension , American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.00792.2006, 292:5, (H2316-H2323), Online publication date: 1-May-2007. May 26, 2006Vol 98, Issue 10 Advertisement Article InformationMetrics https://doi.org/10.1161/01.RES.0000225927.04710.33PMID: 16728665 Originally publishedMay 26, 2006 Keywordssignal transductionpulmonary arterial hypertensionvascular smooth muscle cellsserotonin transporter (SERT5-HTT)PDF download Advertisement